Maxime Ronot
@maximeronot
Followers
632
Following
1K
Media
74
Statuses
546
Diagnostic and interventional abdominal radiologist
Paris
Joined May 2009
RT @NaultJc: Dissection of Progressive Disease Patterns for a Modified Classification for Immunotherapy | Targeted and Immune Therapy | JAM….
0
3
0
🚨EASL CPG on the management of HCC in @JHepatology .Major update!. ✅ LI-RADS endorsed.✅ Refined treatment algo.✅ More evidence supporting locoregional treatments .✅ Up-to-date discussions. 👉
0
12
41
RT @JHepatology: 🆕EASL Clinical Practice Guidelines on the management of #hepatocellularcarcinoma❗️. ✅Updated advice for managing patients….
0
142
0
RT @ArndtVogel: 🔥off the press: Tumor burden with AFP improves survival prediction for TACE treated patients with HCC.@JHEP_Reports .https:….
0
18
0
RT @JHEP_Reports: ❕Patient and physician expectations regarding disease and treatment of advanced HCC: The prospective PERCEPTION1 study. 🔓….
0
5
0
RT @NaultJc: Preferences for speed of access versus certainty of the survival benefit of new cancer drugs: a discrete choice experiment - T….
0
2
0
RT @RadiologyEditor: 🩺MRI-assessed intratumoral fat was generally nonprognostic; however, homogeneous intratumoral fat correlated with long….
0
4
0
RT @ArndtVogel: Risk of HCC in Subcentimeter Liver Nodules Identified on Surveillance Ultrasound.@AGA_CGH.🔎 Systema….
0
10
0
RT @APandT: Read 'open access' at "Early-Life Infections, Antibiotics and Later Risk of Childhood and Early Adult-O….
0
2
0
RT @JHepatology: 💥EXPERT OPINION. Integration of new technologies in the multidisciplinary approach to primary liver tumours. ➡️The next-ge….
0
18
0
RT @ArndtVogel: 🔥off the press.Tumor burden with AFP improves survival prediction for TACE-treated patients with HCC.@JHEP_Reports .🔎🗺️RWD….
0
13
0
RT @NaultJc: The position paper from EASL about "management of rare primary liver cancers" was recently published in Journal Of Hepatology….
0
14
0
RT @ArndtVogel: Updated data for atezo + bev vs surveillance in resected or ablated high risk HCC.#ESMO24.🔎IMbrave050.👉RFS 33.2 vs 36 mo, H….
0
86
0
RT @ArndtVogel: Preoperative mFOLFIRINOX with or without CRT in borderline resectable #PDAC.#ESMO24.🔎Phs II trial PANDAS/PRODIGE 44.👉R0 res….
0
48
0
RT @cannella_rob: Congratulations to @F_matteini and team @marco_dioguardi @maximeronot @DrF_Vernuccio for the article "Discontinuous perip….
0
2
0
RT @radiology_rsna: 🚨 A new episode of the @radiology_rsna podcast is now available! 🚨 @LindaChuMD speaks with Dr. Lorenzo Garzelli and @ma….
0
1
0
Portal vein thrombosis: diagnosis, management, and endpoints for future clinical studies. Amazing collective work 💪.Everything there is to know, and more!. a new set of imaging criteria to play with ⬇️.@ValdigGroup.@RautouE
0
29
69
RT @RautouE: @LancetGastroHep @ERN_RARE_LIVER @ValdigGroup 📢The "VALDIG PVT criteria" we propose here will help homogenize studies on porta….
0
5
0
RT @LancetGastroHep: New Review - Elkrief et al - Portal vein thrombosis: diagnosis, management, and endpoints for future clinical studies….
0
72
0
RT @LiverInt: 1/2.Cholangiocarcinoma is a rare but serious liver cancer😕. 🇫🇷 French experts have created guidelines to help doctors diagnos….
0
58
0